• Markets
    • icon
  • Companies
ACW · ASX

Actinogen Medical Limited (ASX:ACW)

AU$0.039

 0.0 (0.0%)
ASX:Live
06/09/2024 04:10:33 PM
HALO Ords HALO Momentum HALO Earnings Momentum GROWTH AUS All-Consensus +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ACW Overview

ACW Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Weak

Growth

Earnings

Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ACW

Website

Actinogen Medical Limited

Telephone

61.2.8964.7401

Address

Level 9 Suite 901 109 Pitt Street Sydney, New South Wales (NSW) 2000

Description

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company was founded by Geoff E. D. Brooke & David Keast on March 23, 1999 and is headquartered in Sydney, Australia.

ACW Price Chart

Key Stats

Market Cap

AU$100.34M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.01 - 0.1

Trade Value (12mth)

AU$62,928.00

1 week

-13.33%

1 month

-47.3%

YTD

88.29%

1 year

64.75%

All time high

0.84

Key Fundamentals

EPS 3 yr Growth

114.30%

EBITDA Margin

N/A

Operating Cashflow

-$17m

Free Cash Flow Return

-101.60%

ROIC

-78.20%

Interest Coverage

-937.40

Quick Ratio

13.90

Other Data

Shares on Issue (Fully Dilluted)

2683m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ACW Announcements

Latest Announcements

Date Announcements

05 September 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

30 August 24

ACW Appendix 4E and 2024 Annual Report

×

ACW Appendix 4E and 2024 Annual Report

30 August 24

ACW FY2024 results, advancing into late-stage trials

×

ACW FY2024 results, advancing into late-stage trials

30 August 24

Corporate Governance Statement

×

Corporate Governance Statement

30 August 24

Appendix 4G

×

Appendix 4G

29 August 24

ACW updated positive depression trial results presentation

×

ACW updated positive depression trial results presentation

26 August 24

ACW updated depression trial results and implications

×

ACW updated depression trial results and implications

13 August 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

12 August 24

ACW XanaCIDD phase 2a trial topline results

×

ACW XanaCIDD phase 2a trial topline results

08 August 24

Trading Halt

×

Trading Halt

31 July 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

29 July 24

ACW CMO presents academic poster at AAIC in Philadelphia

×

ACW CMO presents academic poster at AAIC in Philadelphia

25 July 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

24 July 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

22 July 24

ACW June 2024 quarterly activity report & Appendix 4C

×

ACW June 2024 quarterly activity report & Appendix 4C

19 July 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

18 July 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

17 July 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

10 July 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

09 July 24

Results of Meeting

×

Results of Meeting

05 July 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

04 July 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

02 July 24

ACW XanaCIDD depression trial results expected early August

×

ACW XanaCIDD depression trial results expected early August

26 June 24

Positive Xanamem biomarker trial published in Jnl Alz Dis

×

Positive Xanamem biomarker trial published in Jnl Alz Dis

17 June 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

ACW Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -100.0 -9.6 -5.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.00 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -123.3 -11.6 8.3 Lock Lock Lock
     Yield % Lock Lock Lock Lock -11.1 -12.1 -12.6 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.01 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.01 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 21.9 -42.8 14.3 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 1,812 1,902 2,174 Lock Lock Lock
Basic m Lock Lock Lock Lock 1,812 1,902 2,174 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 13 15 23 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -3.6 -1.2 -2.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -13 -15 -23 Lock Lock Lock
     Growth % Lock Lock Lock Lock -131.5 -21.1 -47.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -13 -16 -23 Lock Lock Lock
     Growth % Lock Lock Lock Lock -123.1 -20.5 -46.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -13 -16 -23 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -4 -5 -10 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -9 -11 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -142.6 -13.2 -21.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -10 -9 -17 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 12 1 18 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -10 -9 -17 Lock Lock Lock
     Growth % Lock Lock Lock Lock -450.3 8.2 -94.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 16 8 9 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 23 15 21 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -16 -8 -9 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 22 13 20 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 22 13 20 Lock Lock Lock
     Growth % Lock Lock Lock Lock 23.9 -38.6 48.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -40.8 -70.7 -61.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -43.7 -80.2 -66.2 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -66.5 -89.7 -138.4 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -48.1 -61.0 -78.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -48.2 -49.4 -101.6 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -691.2 -931.8 -937.4 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.3 0.5 0.4 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -74.5 -62.5 -46.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 13.8 7.0 13.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 13.8 7.0 13.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 80.2 66.7 50.1 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -643.2 -482.8 -1,249.2 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -40.8 -70.7 -61.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -43.7 -80.2 -66.2 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -43.7 -80.2 -66.2 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 588.0 899.9 743.7 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -588.0 -899.9 -743.7 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ACW Shortsell

Frequently Asked Questions

The current share price of Actinogen Medical Limited (ACW:ASX) is AU$0.039.
The 52-week high share price for Actinogen Medical Limited (ACW:ASX) is AU$0.10.
The 52-week low share price for Actinogen Medical Limited (ACW:ASX)? is AU$0.01.
Actinogen Medical Limited (ACW:ASX) does not pay a dividend.
Actinogen Medical Limited (ACW:ASX) does not pay a dividend.
Actinogen Medical Limited (ACW:ASX) has a franking level of 0.0%.
Actinogen Medical Limited (ACW:ASX) is classified in the Healthcare.
The current P/E ratio for Actinogen Medical Limited (ACW:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.